Drs. Graham Dempsey, Noelle Germain, and James Fink of Quiver Biosciences

Validate a Novel Antisense Oligonucleotide Therapeutic for Fragile X Syndrome

FRAXA funds Quiver Biosciences to validate a novel antisense oligonucleotide (ASO) therapy for Fragile X syndrome, targeting the root cause of the disorder.

Read More »

Categories

FRAXA Funded Research

Current Research Grants (38)